SCHEMBL11907367

SCHEMBL11907367

Nc1ccc(-c2c(F)ccc(OCc3ccccc3F)c2F)nc1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 2/20 0.42
PTGER1 P34995 4/20 0.41
MAPT P10636 2/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CLCN2 P51788 1/20 0.39
KMT2A Q03164 2/20 0.39
OPRM1 P35372 1/20 0.39
OPRD1 P41143 1/20 0.39
MAOB P27338 1/20 0.39
PARP15 Q460N3 1/20 0.39
PARP14 Q460N5 1/20 0.39
PARP10 Q53GL7 1/20 0.39
SLC1A5 Q15758 1/20 0.39
MPO P05164 1/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
DCPS Q96C86 1/20 0.37
PRMT5 O14744 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11907325 0.91 MRGPRX4 (0.41) PTGER1CLCN2SLC1A5MRGPRX4
SCHEMBL11907553 0.83 FGFR2 (0.41) MAPTKDM4EALDH1A1L3MBTL1KMT2A
SCHEMBL11907614 0.81 PIM2 (0.35) MAPTKDM4EALDH1A1KMT2AMEN1
SCHEMBL11909253 0.81 PPARD (0.37) TSHR
SCHEMBL11909552 0.79 LMNA (0.38) MAPTKDM4EALDH1A1L3MBTL1KMT2A
SCHEMBL11907548 0.77 FFAR4 (0.41)
SCHEMBL318994 0.76 PIM2 (0.48)
SCHEMBL11909476 0.73 MRGPRX4 (0.43) PTGER1MRGPRX4
SCHEMBL11907598 0.70 PIM2 (0.54)
SCHEMBL8881744 0.69 SGMS2 (0.52) DHFRMAPTKDM4EALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140249135-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2014-09-04 US disclosed
US-8822497-B2 PIM kinase inhibitors and methods of their use NOVARTIS AG (CH) 2014-09-02 US disclosed
EP-2132177-B1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2013-07-17 EP disclosed
US-20120208815-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2012-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249135-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 DHFR 2784/4885PTGER1 2618/4885MAPT 4106/4885
US-20120208815-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 DHFR 2784/4885PTGER1 2618/4885MAPT 4106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.